Fresenius Kabi debuts generic Mycamine

Press enter to search
Close search
Open Menu

Fresenius Kabi debuts generic Mycamine

By Sandra Levy - 05/12/2020

Fresenius Kabi is offering micafungin for injection in dosage strengths of 50 mg and 100 mg.

The product, which is available in a 10 ml vial, is the first generic of Astellas Pharma's Mycamine.

“We’re pleased to offer the first micafungin generic in the United States, expanding our anti-infective portfolio, and increasing supply of this much-needed medication. Fresenius Kabi is committed to providing products that enable clinicians to deliver high-quality, cost-effective therapies,” said John Ducker, president and CEO of Fresenius Kabi USA.

Micafungin for injection is an echinocandin indicated in adult and pediatric patients for:

  • Treatment of candidemia, acute disseminated candidiasis, candida peritonitis and abscesses in adult and pediatric patients 4 months of age and older;
  • Treatment of candidemia, acute disseminated candidiasis, candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age;
  • Treatment of esophageal candidiasis in adult and pediatric patients 4 months of age and older; and 
  • Prophylaxis of candida infections in adult and pediatric patients 4 months of age and older undergoing Hematopoietic Stem Cell Transplantation.

Related Topics